GEMFIBROZIL-300 - CAP 300 MG
GEMFIBROZIL : 300 MG · DIN 02136031 · PRO DOC LIMITEE
Health Canada status: CANCELLED POST MARKET
What is GEMFIBROZIL-300 - CAP?
GEMFIBROZIL-300 - CAP 300 MG contains GEMFIBROZIL : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02136031, held by PRO DOC LIMITEE, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 13-Jul-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is GEMFIBROZIL-300 - CAP used for?
Adjunct to diet for: 1. Very high serum triglycerides (Type IV/V hyperlipidemia) at risk of pancreatitis. 2. Hypercholesterolemia, Type IIa and IIb mixed dyslipidemias to regulate lipid levels.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is GEMFIBROZIL-300 - CAP called?
The same molecule, GEMFIBROZIL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ausgem | Latin | Australia |
| Lipigem | Latin | Australia |
| LOPID | Latin | Bahrain, Saudi Arabia |
| LOW-LIP | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02136031 |
|---|---|
| Brand name | GEMFIBROZIL-300 - CAP |
| Generic / active ingredient | GEMFIBROZIL : 300 MG |
| Manufacturer | PRO DOC LIMITEE |
| Strength | 300 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AB04 GEMFIBROZIL |
| AHFS class | 24:06.06 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 13-Jul-2010 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02136031 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2136031 |
| Brand name | GEMFIBROZIL-300 - CAP |
| Active ingredient / INN | GEMFIBROZIL : 300 MG |
| ATC code | C10AB04 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10 |
| AHFS class | 24:06.06 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PRO DOC LIMITEE |
How is it administered?
Recommended adult dose: 1200 mg daily in two divided doses (300 mg x 2 or 600 mg x 1 twice daily) 30 minutes before morning and evening meals. Max dose: 1500 mg/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Capsules: 15-30°C. Tablets: 15-25°C, protect from moisture.
How is it supplied?
Capsules: Bottles of 100 and 500. Tablets: Bottles of 100 and 500; unit dose packages of 100.
Which pack is which?
| Strength on the label | 300 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Packaging as described in the monograph | Capsules: Bottles of 100 and 500. Tablets: Bottles of 100 and 500; unit dose packages of 100. |
| Storage | Capsules: 15-30°C. Tablets: 15-25°C, protect from moisture. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hepatic/renal dysfunction; biliary cirrhosis; pre-existing gallbladder disease; hypersensitivity; pregnancy/lactation; Type I hyperlipoproteinemia; concomitant use with repaglinide.
Warnings and precautions
Risk of myositis/rhabdomyolysis with statins; potential for cholelithiasis (gallstones); liver tumor risk in animal studies; periodic blood counts and liver function tests recommended.
What can be used instead?
Other Canadian products sharing ATC code C10AB04 GEMFIBROZIL. 1 of 22 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TEVA-GEMFIBROZIL | 600 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02142074 |
| APO-GEMFIBROZIL | 600 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 01979582 |
| APO-GEMFIBROZIL CAP 300MG USP | 300 MG | CAPSULE | APOTEX INC | CANCELLED POST MARKET | DIN 01979574 |
| DOM-GEMFIBROZIL | 300 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02241608 |
| DOM-GEMFIBROZIL | 600 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02230580 |
| GEMFIBROZIL CAP 300MG | 300 MG | CAPSULE | OMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC. | CANCELLED POST MARKET | DIN 00851922 |
| GEMFIBROZIL TAB 600MG | 600 MG | TABLET | OMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC. | CANCELLED POST MARKET | DIN 00851930 |
| GEMFIBROZIL-600 - TAB 600MG | 600 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02136058 |
| LOPID 600MG | 600 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00659606 |
| LOPID CAP 300MG | 300 MG | CAPSULE | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00599026 |
Who else supplies GEMFIBROZIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GEMFIBROZIL appears in 24 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does GEMFIBROZIL cost around the world?
GEMFIBROZIL is listed on 9 national price registers Nexara tracks, across 42 pack listings published on 8 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 1 | 23 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 5 | 7 | 02 Sep 2026 |
| Australia | ex-manufacturer | 2 | 4 | 08 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 1 | 2 | 03 Sep 2026 |
| Bahrain | retail (max) | 2 | 2 | 01 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Saudi Arabia | public | 1 | 1 | 01 Sep 2026 |
| South Africa | single exit price | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.